This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Tinnitus Treatment With Piribedil Guided by Acoustic Otoemissions and Electrocochleography (piribedil)

This study has been completed.
Information provided by:
Faculdade de Medicina de Valenca Identifier:
First received: December 26, 2007
Last updated: March 6, 2008
Last verified: December 2007
Tinnitus is defined as the perception of sound in the absence of a external source. About 15 % of the population is believed to experience tinnitus and for about 20 % of them it may become a very serious problem. Total comprehension of tinnitus pathophysiology has not yet been achieved, but modern theories focus in brain hyperactivity following inner ear damage, with involvement of various neurotransmitters. Piribedil,a dopamin agonist, has been used to treat tinnitus, focusing in dopamine release, which is inhibitory. Electrophysiological methods,like acoustic otoemissions and electrocochleography may reveal the changes in peripherical and central auditory pathways and help to choose the specific patients who could benefit from piribedil treatment.

Condition Intervention
Tinnitus Drug: piribedil

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Tinnitus Treatment With Piribedil Guided by Acoustic Otoemissions and Electrocochleography

Resource links provided by NLM:

Further study details as provided by Faculdade de Medicina de Valenca:

Primary Outcome Measures:
  • THI - Tinnitus Handicap Inventory [ Time Frame: Months 3 and 6 ]

Secondary Outcome Measures:
  • VAS - Visual Analog Scale [ Time Frame: Months 3 and 6 ]

Enrollment: 100
Study Start Date: November 2006
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: piribedil
    50 mg once a day, after lunch 3 month therapy

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • tinnitus for more than 6 months
  • THI > 38
  • no central acting drugs in the last 6 months
  • tympanogram type A-n

Exclusion Criteria:

  • vascular and muscular tinnitus
  • concomitant TMJ disorders
  • abnormal otoscopy
  • mixed and conductive hearing losses
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00591994

OTOSUL,Otorrinolaringologia Sul-Fluminense
Volta Redonda, RJ, Brazil, 27255-650
Sponsors and Collaborators
Faculdade de Medicina de Valenca
Study Chair: Ricardo R Figueiredo, M.D.,M.Sc Faculdade de Medicina de Valença
Principal Investigator: Andréia A Azevedo, M.D. Otosul -Otorrinolaringologia Sul-Fluminense
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Andréia Aparecida de Azevedo, M.D., OTOSUL Identifier: NCT00591994     History of Changes
Other Study ID Numbers: OTOSUL 01/2007
FMV 01/2006
Study First Received: December 26, 2007
Last Updated: March 6, 2008

Keywords provided by Faculdade de Medicina de Valenca:
acoustic otoemissions

Additional relevant MeSH terms:
Hearing Disorders
Ear Diseases
Otorhinolaryngologic Diseases
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs processed this record on August 23, 2017